Do Prescribing Trends Foretell the Future?
When a new version of inhaled insulin was approved less than 2 years ago, it had the potential to become a major component of diabetes treatment. However, given the recent announcement that pharmaceutical giant Sanofi will stop distributing Afrezza® after a year of poor sales, it is unlikely that the product developed by Mannkind will change the diabetes landscape.
Another diabetes treatment has received even more fanfare lately, and one must wonder if it will be a true "game changer" this time around. Last fall, clinicians enthusiastically received news that the glucose-lowering drug empagliflozin significantly reduced the relative risk for both cardiovascular mortality and all-cause mortality in patients with type 2 diabetes, according to the EMPA-REG OUTCOME trial./.../